Guardant Health Inc
GH49.540USD
-0.960-1.90%
Close 07/07, 16:00（ET）Quotes delayed by 15 min
6.13BMarket Cap
LossP/E TTM
More Details of Guardant Health Inc Company
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Company Info
Ticker SymbolGH
Company nameGuardant Health Inc
IPO dateOct 04, 2018
Founded at2011
CEODr. Amirali Talasaz, Ph.D.
Number of employees1999
Security typeOrdinary Share
Fiscal year-endOct 04
Address3100 Hanover Street
CityPALO ALTO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94304
Phone18556988887
Websitehttps://guardanthealth.com/
Ticker SymbolGH
IPO dateOct 04, 2018
Founded at2011
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.75M
+0.43%
Dr. Amirali Talasaz, Ph.D.
Dr. Amirali Talasaz, Ph.D.
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
2.50M
-3.40%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
80.44K
+1.88%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
44.82K
+2.88%
Mr. Craig Eagle, M.D.
Mr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
36.79K
+4.75%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
+37.83%
Ms. Myrtle Stephens Potter
Ms. Myrtle Stephens Potter
Independent Director
Independent Director
18.15K
+29.09%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
17.82K
+8.04%
Ms. Meghan V. Joyce
Ms. Meghan V. Joyce
Independent Director
Independent Director
11.15K
+42.11%
Mr. Musa Tariq
Mr. Musa Tariq
Independent Director
Independent Director
7.19K
+106.67%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.75M
+0.43%
Dr. Amirali Talasaz, Ph.D.
Dr. Amirali Talasaz, Ph.D.
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
2.50M
-3.40%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
80.44K
+1.88%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
44.82K
+2.88%
Mr. Craig Eagle, M.D.
Mr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
36.79K
+4.75%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
+37.83%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Oncology
150.56M
74.00%
Biopharma and data
45.38M
22.30%
Screening
5.68M
2.79%
Licensing and other
1.86M
0.91%
By RegionUSD
Name
Revenue
Proportion
United States
193.61M
95.15%
International
9.86M
4.85%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Oncology
150.56M
74.00%
Biopharma and data
45.38M
22.30%
Screening
5.68M
2.79%
Licensing and other
1.86M
0.91%
Shareholding Stats
Updated: Sat, Jun 21
Updated: Sat, Jun 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.73%
BlackRock Institutional Trust Company, N.A.
6.95%
Deep Track Capital LP
4.39%
Capital International Investors
4.16%
Baillie Gifford & Co.
4.09%
Other
70.69%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.73%
BlackRock Institutional Trust Company, N.A.
6.95%
Deep Track Capital LP
4.39%
Capital International Investors
4.16%
Baillie Gifford & Co.
4.09%
Other
70.69%
Shareholder Types
Shareholders
Proportion
Investment Advisor
38.09%
Investment Advisor/Hedge Fund
33.25%
Hedge Fund
21.67%
Individual Investor
4.57%
Research Firm
2.22%
Bank and Trust
1.82%
Sovereign Wealth Fund
1.81%
Pension Fund
1.28%
Insurance Company
0.03%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
741
129.90M
104.85%
-16.16M
2025Q1
783
130.34M
105.23%
-16.59M
2024Q4
746
130.16M
105.47%
-20.09M
2024Q3
780
137.29M
111.53%
-9.70M
2024Q2
801
127.50M
103.74%
-18.45M
2024Q1
826
124.00M
101.88%
-12.71M
2023Q4
856
120.18M
99.30%
-14.26M
2023Q3
867
117.78M
100.31%
-19.15M
2023Q2
890
119.83M
102.55%
+840.96K
2023Q1
908
101.46M
98.78%
-16.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
12.05M
9.73%
+28.83K
+0.24%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.61M
6.95%
-284.70K
-3.20%
Mar 31, 2025
Deep Track Capital LP
5.44M
4.39%
-975.85K
-15.20%
Mar 31, 2025
Capital International Investors
5.15M
4.16%
+674.48K
+15.08%
Mar 31, 2025
Baillie Gifford & Co.
5.06M
4.09%
-388.09K
-7.12%
Mar 31, 2025
Cadian Capital Management LP
4.60M
3.71%
-626.48K
-12.00%
Mar 31, 2025
Two Sigma Investments, LP
4.19M
3.38%
-12.65K
-0.30%
Mar 31, 2025
Citadel Advisors LLC
3.60M
2.9%
+2.12M
+142.72%
Mar 31, 2025
Eventide Asset Management, LLC
3.57M
2.88%
-241.20K
-6.33%
Mar 31, 2025
Capital Research Global Investors
2.93M
2.37%
+190.45K
+6.95%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
ARK Genomic Revolution ETF
6.11%
Global X Genomics & Biotechnology ETF
3.8%
Invesco Dorsey Wright Healthcare Momentum ETF
3.24%
Franklin Genomic Advancements ETF
2.43%
First Trust Nasdaq Lux Digi Health Solutions ETF
2.21%
ROBO Global Healthcare Technology & Innovation ETF
2.12%
Alger Mid Cap 40 ETF
1.85%
SPDR S&P Health Care Services ETF
1.82%
BNY Mellon Innovators ETF
1.39%
iShares Health Innovation Active ETF
1.23%
View more
ARK Genomic Revolution ETF
Proportion6.11%
Global X Genomics & Biotechnology ETF
Proportion3.8%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion3.24%
Franklin Genomic Advancements ETF
Proportion2.43%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion2.21%
ROBO Global Healthcare Technology & Innovation ETF
Proportion2.12%
Alger Mid Cap 40 ETF
Proportion1.85%
SPDR S&P Health Care Services ETF
Proportion1.82%
BNY Mellon Innovators ETF
Proportion1.39%
iShares Health Innovation Active ETF
Proportion1.23%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
